Day 2 #ESMO26 Highlights:
1. CheckMate8HW: Nivo+Ipi in mCRC
Breast Ca
2. postMONARCH: Abema+Fulv HR+
3. VIKTORIA-1: Gedatolisib HR+
4. TROPION-Breast02: DatoDXd TNBC
GU/Gyn
5. PROTEUS: Periop Apa+ADT in Prostate Cancer
#OncTwitter #bcsm #gusm #gism @myESMO
1/10
345 views · 3 likes · 3 reposts · 9 replies
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org- Oncology Brothers@OncBrothers
Day 2 #ESMO26 highlights 6. DUO-E: Durvalumab + Olaparib in Endometrial Ca Lung 7. COCOON: Supportive care for Ami/Laz 8. Destiny-LUNG04: TDXd in NSCLC *Presidential from Day 2 👇👇* #OncTwitter #gynsm @myESMO 2/10
- Oncology Brothers@OncBrothers
8. DESTINY-Lung04: Ph3, 1L Her2 mutated mNSCLC, TDXd vs SoC - Delayed TTD cough: 26.2 vs 11.0 mos (HR 0.66) - Numerical benefit in dyspnea & chest pain - Better physical functioning later with T-DXd - PFS (14.3 vs 8.3 mo) but OS at WCLC26 not superior. 10/10
- Oncology Brothers@OncBrothers
7. COCOON: Supportive care & Dermatologic management for Amivantamab + Laz in NSCLC: - Derm prophylaxis cuts Gr≥2 derm AEs ~75% to 42%. - SubCutaneous Ami + simplified regimen: Gr≥2 by wk12 39% to 18% w/ Laz lead-in. - ⬇️ discontinuations and improve tolerability. 9/10
- Oncology Brothers@OncBrothers
6. DUO-E (Updated OS): PhIII, Durva + chemo → Durva + olaparib vs chemo alone in advanced/recurrent endometrial cancer. - mOS 51.1 vs 39.6 mo (HR 0.77) - Interim analysis did not meet formal statistical threshold - Numerical benefit seen in pMMR 8/10
- Oncology Brothers@OncBrothers
5. PROTEUS: Periop Apalutamide + ADT + RP+PLND vs RP+PLND alone in high-risk localized/locally advanced Prostate Cancer: - EFS 3yr 63% vs 41% (HR 0.38) - MFS HR 0.49 - TT subsequent Rx HR 0.29. - OS immature - DASL-HiCaP also presented today. 7/10
- Oncology Brothers@OncBrothers
4. TROPION-Breast02: 1L DatoDXd vs chemo in IO-ineligible mTNBC. - mPFS 10.8 vs 5.6 mo (HR 0.57) - mOS 23.7 vs 18.7 mo (HR 0.79) - Brain mets (n=61): CNS PFS 9.5 vs 2.6 mos (HR 0.27) - icORR 62.5% vs 37.5% - Strong intracranial activity!!! 6/10
- Oncology Brothers@OncBrothers
3. VIKTORIA-1 Update (PIK3CA-mut cohort), gedatolisib ± palbociclib + fulvestrant vs alpelisib + fulvestrant in HR+/HER2– aBC post-CDK4/6i - Strong PFS maintained in visceral/liver mets (no liver mets: 21.5 vs 9.1 mo, HR ~0.46) - ⬆️ ORR & DOR - ⬇️ hyperglycemia 5/10
- Oncology Brothers@OncBrothers
2. postMONARCH: Final OS, abemaciclib+fulvestrant vs PBO + fulvestrant post CDK4/6i in HR+ - mOS 32.1 vs 24.6 mo (HR 0.80, NS). - Numerical OS signal but not statistically significant. - Updated PFS HR 0.78 - If ESR1, Abema + Imlu approved! 4/10
- Oncology Brothers@OncBrothers
1. CheckMate 8HW (final OS): Nivo+Ipi in MSI-H/dMMR mCRC: - 1L vs chemo: HR 0.37 - 1L vs Nivo: HR 0.66 (missed formal boundary). - Supports dual ICI as SOC 3/10
Source: Oncology Brothers · x.com